GlassScriptPhysician profile
Ilen Diaz
NPI 1669953535
$12,083.23
in general payments reported to CMS, 2019-2025
19 companies · $4,404 in 2025
The $4,404 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $841 · 2023: $2,233 · 2024: $3,541 · 2025: $4,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,048 · Consulting Fee: $900 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,048.36 |
| Consulting Fee | $900.00 |
| Education | $228.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,550.06 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $2,792.37 | 2021-2025 | |
| Pfizer INC. | $967.69 | 2021-2025 | |
| Lilly USA, LLC | $514.62 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $418.25 | 2021-2025 | |
| Leo Pharma INC. | $287.13 | 2021-2023 | Adbry |
| Incyte Corporation | $110.28 | 2024-2025 | Opzelura |
| Genzyme Corporation | $107.67 | 2021-2025 | |
| Dermavant Sciences, INC. | $64.57 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.64 | 2025 | Spevigo |
| Kyowa Kirin, INC. | $25.48 | 2021 | |
| Amgen INC. | $25.02 | 2025 | Otezla |
| Ucb, INC. | $23.75 | 2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $23.42 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.37 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.74 | 2023 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $14.24 | 2023 | Dupixent |
| Organon LLC | $2.38 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilen Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.